These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17268395)

  • 21. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
    Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC;
    BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevating our therapeutic expectations in overactive bladder.
    Sand PK
    J Am Acad Nurse Pract; 2004 Oct; 16(10 Suppl):8-11. PubMed ID: 15543927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study.
    But I; Goldstajn MS; Oresković S
    Coll Antropol; 2012 Dec; 36(4):1347-53. PubMed ID: 23390832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duloxetine: a new approach for treating stress urinary incontinence.
    Moore K
    Int J Gynaecol Obstet; 2004 Jul; 86 Suppl 1():S53-62. PubMed ID: 15302567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
    Staskin DR; MacDiarmid SA
    Am J Med; 2006 Mar; 119(3 Suppl 1):9-15. PubMed ID: 16483863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duloxetine in women awaiting surgery.
    Drutz H
    BJOG; 2006 May; 113 Suppl 1():17-21. PubMed ID: 16529565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New strategies for medical management of overactive bladder in children.
    Schröder A; Thüroff JW
    Curr Opin Urol; 2010 Jul; 20(4):313-7. PubMed ID: 21475074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
    Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
    Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
    Wagg A; Dale M; Tretter R; Stow B; Compion G
    Eur Urol; 2013 Jul; 64(1):74-81. PubMed ID: 23332882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
    Hart WM; Abrams P; Munro V; Retsa P; Nazir J
    J Med Econ; 2013 Oct; 16(10):1246-54. PubMed ID: 23885660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus.
    Jost W; Marsalek P
    Clin Auton Res; 2004 Aug; 14(4):220-7. PubMed ID: 15316838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxybutynin in detrusor overactivity.
    Diokno A; Ingber M
    Urol Clin North Am; 2006 Nov; 33(4):439-45, vii. PubMed ID: 17011379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anticholinergics for overactive bladder: does subtype selectivity play a role?].
    Michel MC; Barendrecht MM; Oelke M
    Urologe A; 2006 Jul; 45(7):826-9. PubMed ID: 16767455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solifenacin at 3 years: a review of efficacy and safety.
    Pelman RS; Capo JP; Forero-Schwanhaeuser S
    Postgrad Med; 2008 Jul; 120(2):85-91. PubMed ID: 18654073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg.
    Cornu JN
    Eur Urol; 2013 Jul; 64(1):82-3. PubMed ID: 23398768
    [No Abstract]   [Full Text] [Related]  

  • 38. New treatment options for overactive bladder.
    Oehlke KJ
    S D J Med; 2005 Jun; 58(6):225-6. PubMed ID: 16050656
    [No Abstract]   [Full Text] [Related]  

  • 39. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
    Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Darifenacin: Pharmacology and clinical usage.
    Steers WD
    Urol Clin North Am; 2006 Nov; 33(4):475-82, viii. PubMed ID: 17011383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.